OSSIOfiber Trimmable Fixation Nail System Launches in the U.S.

For Broad Utilization in Foot/Ankle and Hand/Wrist Procedures New Biointegrative System Offers Screw-Like Stability with the Utility of a Trimmable Nail, Leaving No Permanent Implant Behind

July 22, 2020

OSSIOfiber Trimmable Fixation Nail System official US launch and first commercial use, to securely fixate bone fractures, osteotomies and arthrodeses for healing, ultimately leaving the patient’s bone restored with no permanent hardware left behind was announced today by Ossio, Inc. The first commercial cases were bunion and MTP fusion procedures performed successfully by Chris Hyer, DPM, Foot and Ankle Surgeon at Polaris Surgery Center in Westerville, Ohio.

Part of the OSSIOfiber Bone Pin Product Family, which received 510(k) market clearance from the U.S. Food and Drug Administration (FDA) in 2019, the OSSIOfiber® Trimmable Fixation Nail System includes strong, biointegrative Trimmable Fixation Nails in 2.4mm and 4.0mm diameters packaged with corresponding sterile, disposable instrumentation. These trimmable nails rival the performance of metal compression screws, combining the necessary strength for bone fixation with the ability to provide rapid bone in-growth, regeneration, and replacement without adverse inflammation, therefore avoiding the costs, pain, and complications often seen with permanent hardware.

Additionally, the ability to trim the implants to any desired length enables customization to any patient anatomy and adaptability for a wide range of surgical indications including forefoot, midfoot, hindfoot, and an array of hand/wrist applications.

“Having successfully utilized this new biointegrative option in my own clinical practice, it is clear that the OSSIOfiber® Trimmable Fixation Nails have real potential to replace metal compression screws and pins in numerous orthopedic procedures, with the ability to optimize bone healing while avoiding permanent implant-related post-operative complications,” said Dr. Hyer. “This novel trimmable nail system is exceptionally strong and well-designed, providing both the stability needed for solid fixation, natural healing and integration into the surrounding anatomy. The ease-of-use of the pre-sterilized, disposable instrumentation is excellent, and I like how the tapered ends of the nail allow for straightforward insertion into the bone tunnel and that it can be easily trimmed for broad procedural utility.”

OSSIO’s proprietary OSSIOfiber technology is engineered from a high performing matrix of reinforcing mineral fibers yielding strength that is 1.5 times greater than cortical bone. The design features of the OSSIOfiber® Trimmable Fixation Nail System contribute to the ability to maintain compression, stability and fixation strength and strong pull-out strength. Additionally, the hexagonal shape of the trimmable nails resist rotation, which prevents loosening that often results in screw back-out.

Additional procedures utilizing the OSSIOfiber® Trimmable Fixation Nail System are planned across the United States in the coming weeks.

“We are pleased to bring our next biointegrative fixation system to market, providing surgeons and their patients with an alternative to metal screws and pins that deliver strength, stability and utility for multiple surgical applications – all while fully integrating into the patient’s bone and leaving nothing permanent behind,” said Brian Verrier, CEO, OSSIO. “Adoption of our OSSIOfiber® Bone Pin Family has been strong to date, with substantial customer utilization across the U.S. We look forward to bringing additional breakthrough technology platforms to market that utilize our proprietary OSSIOfiber® technology and deliver a new standard of care in orthopedic fixation.”

Earlier this year, the company received FDA 510(k) Clearance for its OSSIOfiber® Hammertoe Fixation System. Approximately 700 hammertoe repairs have been conducted to date utilizing the implant.

“OSSIO continues to add promising, innovative solutions that offer an alternative to metal implants to our surgical toolbox,” said Erik Carlson, MD, Hand and Upper Extremity Specialist, Active Orthopaedics PC, and Chief of Orthopaedic Surgery, St. Mary’s Hospital, Waterbury CT. “OSSIOfiber® technology has a strong performance track-record and continues to demonstrate excellent clinical outcomes in the foot and ankle space, with high surgeon and patient satisfaction across the board. I look forward to actively utilizing the customizable OSSIOfiber Trimmable Fixation Nail System in applicable hand and wrist procedures.”

OSSIOfiber® Intelligent Bone Regeneration Technology can address many surgical applications through the manufacturing of endless implant designs, including nails, screws, anchors and plates. The company intends to pursue multiple applications in the distal extremity, trauma, sports, reconstruction, pediatrics and spine segments.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version